Biotech Stock Rips Following Key Announcement

2025-06-30 12:30:00 ET

A Nebraska-based biotech company is turning heads so far during Monday’s session after it announced that it is moving forward with manufacturing and process development work in preparation for clinical trails of its KLTO-202, its investigational gen therapy for amyotrophic lateral sclerosis (ALS).

Traders wasted little time buying up shares of Klotho Neurosciences Inc. (Nasdaq:KLTO) , pushing the micro cap up to $1.39/share (+93.03%) at the early session high. This move could indicate that the recently momentum of this stock is here to stay following the pop earlier this month.

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease, multiple sclerosis and rare neurodegenerative diseases. The company's current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View more of this article on AllPennyStocks.com.

About AllPennyStocks.com Media, Inc.:

Founded in 1999, AllPennyStocks.com is oneof North America’s leading platforms for micro-cap insights.

Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders.

AllPennyStocks.com is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.

Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today.

Contact:

AllPennyStocks.com Media, Inc.

Email: ads@allpennystocks.com

Phone: (800) 558-4560 Ext: 101